FIRST TRACKS BIOTHERAPEUTICS
TRAXNASDAQ🏆 #2353 by market capUS Equity
$1,021.64▲ $63.24 (+6.19%)
Simulated priceTrack TRAX
Get earnings, price moves & breaking news on Telegram
24h▲ 6.2%
7d▲ 2684.9%
14d▲ 2520.6%
30d▲ 2340.0%
ytd—
1y—
🏦Market Cap
$1.20B
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
80
Good
Trading Snapshot
- Day Range
- $1,008.09 – $1,041.53
- 52-Week Range
- $14.72 – $49.91
- Volume
- $3.54B
- Avg Volume
- $4.27B
- Shares Outstanding
- 34.9M
- Next Earnings
- Nov 23, 2026
Fundamentals Snapshot
- Annual Revenue
- $95M
- Last Q Revenue
- $24M
- P/E Ratio
- -9.2
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-3.70
- Dividend Yield
- 0.00%
Why Investors Own TRAX
- ✓High-growth profile — revenue up +44.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 69% gross margin and 16% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
FIRST TRACKS BIOTHERAPEUTICS
TRAXFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$179M▼ −1.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$143M▲ +13.4% YoY
StockOtter · stockotter.spaceAbout FIRST TRACKS BIOTHERAPEUTICS
First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
80/100
Analyst Price Target
ⓘAverage Target
$1,042.46
▲ +2.0% Upside
High Target$1,204.01
Low Target$940.88
Based on 22 analysts
Latest News & Updates
🚀
Barron’s·2h ago
FIRST TRACKS BIOTHERAPEUTICS tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift TRAX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
FIRST TRACKS BIOTHERAPEUTICS announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.